$0.0719
0.0089[14.13%]
At close: Nov 17
$0.0719
0[0.00%]
PreMarket: 9:14AM EDT
Aridis Pharmaceuticals
(OTCQB:ARDS)Aridis Pharmaceuticals Stock (OTC:ARDS), Analyst Ratings, Price Targets, Predictions
Aridis Pharmaceuticals Inc has a consensus price target of $1, established from looking at the 5 latest analyst ratings. The last 3 analyst ratings were released from HC Wainwright & Co., HC Wainwright & Co., and HC Wainwright & Co. on November 6, 2023, October 20, 2023, and January 26, 2023. With an average price target of $4.67 between HC Wainwright & Co., HC Wainwright & Co., and HC Wainwright & Co., there's an implied 7307.41% upside for Aridis Pharmaceuticals Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Maxim Group
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Aridis Pharmaceuticals
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 11/06/2023 | ARDS | Buy Now | Aridis Pharmaceuticals | $0.06 | 3074.6% | HC Wainwright & Co. | Vernon Bernardino | → $2 | Reiterates | Buy → Buy | Get Alert |
| 10/20/2023 | ARDS | Buy Now | Aridis Pharmaceuticals | $0.06 | 3074.6% | HC Wainwright & Co. | Vernon Bernardino | $10 → $2 | Maintains | Buy | Get Alert |
| 01/26/2023 | ARDS | Buy Now | Aridis Pharmaceuticals | $0.06 | 15773.02% | HC Wainwright & Co. | Vernon Bernardino | $19 → $10 | Maintains | Buy | Get Alert |
| 08/16/2022 | ARDS | Buy Now | Aridis Pharmaceuticals | $0.06 | — | Maxim Group | Jason McCarthy | — | Downgrade | Buy → Hold | Get Alert |
| 07/20/2021 | ARDS | Buy Now | Aridis Pharmaceuticals | $0.06 | 30058.73% | HC Wainwright & Co. | Vernon Bernardino | — | Maintains | Buy | Get Alert |
FAQ
What is the target price for Aridis Pharmaceuticals (ARDS)?
The latest price target for Aridis Pharmaceuticals (OTCQB: ARDS) was reported by HC Wainwright & Co. on November 6, 2023. The analyst firm set a price target for $2.00 expecting ARDS to rise to within 12 months (a possible 2681.64% upside). 2 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Aridis Pharmaceuticals (ARDS)?
The latest analyst rating for Aridis Pharmaceuticals (OTCQB: ARDS) was provided by HC Wainwright & Co., and Aridis Pharmaceuticals reiterated their buy rating.
When was the last upgrade for Aridis Pharmaceuticals (ARDS)?
There is no last upgrade for Aridis Pharmaceuticals.
When was the last downgrade for Aridis Pharmaceuticals (ARDS)?
The last downgrade for Aridis Pharmaceuticals Inc happened on August 16, 2022 when Maxim Group changed their price target from N/A to N/A for Aridis Pharmaceuticals Inc.
When is the next analyst rating going to be posted or updated for Aridis Pharmaceuticals (ARDS)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Aridis Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Aridis Pharmaceuticals was filed on November 6, 2023 so you should expect the next rating to be made available sometime around November 6, 2024.
Is the Analyst Rating Aridis Pharmaceuticals (ARDS) correct?
While ratings are subjective and will change, the latest Aridis Pharmaceuticals (ARDS) rating was a reiterated with a price target of $0.00 to $2.00. The current price Aridis Pharmaceuticals (ARDS) is trading at is $0.07, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.